Literature DB >> 3500802

Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates.

D L Heymann, K Murphy, M Brigaud, M Aymard, A Tembon, G K Maben.   

Abstract

During the first 5 years of a poliomyelitis control programme in Yaounde, Cameroon, a maximum of 35% of children aged 12-23 months were estimated to have received three doses of trivalent oral vaccine. Despite this low immunization coverage and low seroconversion rates, which were determined concurrently, the estimated incidence of paralytic poliomyelitis decreased by 85%.A detailed study of immunized children and of children living in the same households suggests that community spread of the vaccine virus and cross-immunity may have partly been responsible for the dramatic decrease in the incidence of paralytic disease, and that competing non-polio enterovirus infection was not a cause for the low seroconversion rates. These results suggest that immunization coverage and seroconversion rates alone are not sufficient criteria for determining the effectiveness of control programmes that use oral poliovirus vaccine in tropical Africa; surveillance of the incidence of paralytic disease must also be carried out.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500802      PMCID: PMC2491033     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  13 in total

1.  Ecology of enteroviruses in tropics. I. Circulation of enteroviruses in healthy infants in tropical urban area.

Authors:  S Otatume; P Addy
Journal:  Jpn J Microbiol       Date:  1975-06

2.  Oral poliomyelitis vaccine, Lederle-thirteen years of laboratory and field investigation. An interim review.

Authors:  B J CABASSO; E L JUNGHERR; A W MOYER; M ROCA-GARCIA; H R COX
Journal:  N Engl J Med       Date:  1960-12-29       Impact factor: 91.245

3.  Poliomyelitis: severity and type of disease in different age groups.

Authors:  D M HORSTMANN
Journal:  Ann N Y Acad Sci       Date:  1955-09-27       Impact factor: 5.691

4.  Poliomyelitis: epidemiology and prophylaxis. 4. Serological and virological surveys conducted after a mass vaccination campaign for the control of a threatening poliomyelitis epidemic.

Authors:  D Metselaar; K McDonald; W Gemert; B Nottay; J M Muli
Journal:  Bull World Health Organ       Date:  1977       Impact factor: 9.408

5.  Persistence of malaria antibody in Tobago, West Indies, following eradication, as measured by the indirect hemagglutination test.

Authors:  H M Mathews; G U Fisher; I G Kagan
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

6.  House-to-house and school lameness surveys in Cameroon: a comparison of two methods for estimating the prevalence and annual incidence of paralytic poliomyelitis.

Authors:  D L Heymann
Journal:  Rev Infect Dis       Date:  1984 May-Jun

7.  Control of poliomyelitis in Africa.

Authors:  S O Foster; G Kesseng-Maben; H N'jie; E Coffi
Journal:  Rev Infect Dis       Date:  1984 May-Jun

8.  Cluster sampling to assess immunization coverage: a review of experience with a simplified sampling method.

Authors:  R H Henderson; T Sundaresan
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

9.  Estimation of incidence of poliomyelitis by three survey methods in different regions of the United Republic of Cameroon.

Authors:  D L Heymann; V D Floyd; M Lichnevski; G K Maben; F Mvongo
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

10.  Determination of type 1 poliovirus subtype classes with neutralizing monoclonal antibodies.

Authors:  R Crainic; P Couillin; N Cabau; A Boue; F Horodniceanu
Journal:  Dev Biol Stand       Date:  1981
View more
  5 in total

Review 1.  Poliomyelitis: eradication in sight.

Authors:  J L Melnick
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

2.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

3.  Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya.

Authors:  P W Kok; J Leeuwenburg; P Tukei; A L van Wezel; J G Kapsenberg; G van Steenis; A Galazka; S E Robertson; D Robinson
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

Review 4.  Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic.

Authors:  Dimitrina Miteva; Monika Peshevska-Sekulovska; Violeta Snegarova; Hristiana Batselova; Radostina Alexandrova; Tsvetelina Velikova
Journal:  World J Virol       Date:  2022-09-25

5.  A spatial model of Wild Poliovirus Type 1 in Kano State, Nigeria: calibration and assessment of elimination probability.

Authors:  Kevin A McCarthy; Guillaume Chabot-Couture; Faisal Shuaib
Journal:  BMC Infect Dis       Date:  2016-09-29       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.